Table 4.
Hemoglobin level, by malaria infection and aspirin exposure
| Hemoglobin cut-point | Overall | Malaria Negative | Malaria positive | |||
|---|---|---|---|---|---|---|
| N (w/ and w/o outcome) | PR (95% CI) | N (w/ and w/o outcome) | PR (95% CI) | N (w/ and w/o outcome) | PR (95% CI) | |
| Hemoglobin ≤ 8 g/dL | ||||||
| Aspirin | 11/618 | 0·91 (0·04, 2·04) | 3/376 | 0·58 (0·14, 2·43) | 8/242 | 1·16 (0·43, 3·14) |
| Placebo | 12/610 | 5/364 | 7/246 | |||
| Hemoglobin ≤ 9 g/dL | ||||||
| Aspirin | 43/586 | 1·06 (0·70, 1·58) | 10/369 | 0·57 (0·27, 1·23) | 33/217 | 1·34 (0·82, 2·18) |
| Placebo | 42/580 | 17/352 | 25/228 | |||
| Hemoglobin ≤ 10 g/dL | ||||||
| Aspirin | 122/507 | 1·01 (0·80, 1·26) | 49/330 | 1·04 (0·71, 1·51) | 73/177 | 1·00 (0·76, 1·31) |
| Placebo | 120/502 | 46/323 | 74/179 | |||
| Hemoglobin ≤ 11 g/dL | ||||||
| Aspirin | 266/363 | 1·03 (0·90, 1·17) | 128/251 | 1·07 (0·87, 1·31) | 138/112 | 1·00 (0·86, 1·18) |
| Placebo | 256/366 | 117/252 | 139/114 | |||
Note: Hemoglobin measured between 26–30 weeks. Malaria in early pregnancy measured between 6–13 6/7 weeks gestation